Federal regulators have granted clearance to a novel diagnostic support tool designed to assist clinicians in identifying autism spectrum disorder in children, marking another step forward in the integration of biometric technology into pediatric healthcare.
The Food and Drug Administration cleared Neurora this month to inform clinical decisions regarding the diagnosis of children ranging from 18 months to 12 years of age. Developed by Argus Cognitive, Inc., the device leverages more than 100 distinct biometrics to assess behavioral indicators associated with autism, offering practitioners an additional layer of quantitative evidence during the evaluation process.
The system is designed to integrate smoothly into existing clinical workflows without requiring specialized hardware or modifications to established testing protocols. Clinicians can upload standard video and audio recordings from routine behavioral assessments directly into the secure Neurora portal. Once uploaded, the fully automated tool measures subtle behavioral markers, including facial expressions, vocal patterns, and eye gaze dynamics. It then evaluates how a child’s behavioral responses compare against normative data gathered from both neurotypical children and those diagnosed with autism.
Rather than serving as an autonomous diagnostic decision-maker, the tool is intended to be weighed alongside other clinical findings and professional judgment, according to representatives from Argus Cognitive.
Dr. Attila Meretei, CEO and co-founder of Argus Cognitive, emphasized that the technology was built to empower rather than replace healthcare providers. "We built Neurora to support clinicians evaluating children for autism," Meretei said. "Neurora works inside the assessment clinicians already use, without protocol changes or proprietary hardware, and is fully automated. Our goal is to reinforce every diagnosis with robust, quantitative evidence."
The development of Neurora received critical backing from federal research funding, supported by a competitive National Institutes of Health grant intended for innovative entrepreneurs. The scientific validation behind the tool was recently highlighted in a peer-reviewed study published earlier this year in the journal Frontiers in Psychiatry. According to the research findings, the automated system successfully distinguished between children with and without autism in nearly 78 percent of evaluated cases, providing empirical backing for its clinical utility.
Neurora joins a small, growing class of FDA-cleared technological devices designed to aid diagnosticians in the complex and often nuanced process of identifying autism spectrum disorder early in life. The regulatory clearance places Neurora alongside other pioneering diagnostic aids previously cleared by the agency.
In June 2022, the FDA cleared the EarliPoint Evaluation for ASD, a specialized tool that uses advanced eye-tracking technology to measure and analyze visual behavior in young children. Prior to that, in June 2021, the agency cleared Canvas Dx, an algorithm-driven software device that analyzes comprehensive parent- and healthcare provider-reported questionnaires alongside home videos of the child to assist practitioners in determining autism diagnoses.
The introduction of these technological aids comes at a time when the healthcare system is grappling with mounting demand for comprehensive developmental evaluations. According to prevalence estimates from the Centers for Disease Control and Prevention, autism currently affects approximately 1 in 31 children in the United States. Despite growing awareness and expanding screening efforts, many families continue to encounter prolonged waiting lists to secure comprehensive developmental evaluations for their children. Furthermore, data from the federal public health agency indicates that the median age of an autism diagnosis in the United States remains just under 4 years old.
Public health advocates and clinicians have long emphasized that early identification is critical, as it allows children to access timely behavioral, speech, and occupational therapies during early childhood when interventions can have a profound impact on long-term developmental outcomes. By streamlining portions of the evaluation process and providing objective biometric data to back up behavioral observations, tools like Neurora aim to help clinicians make more confident, timely determinations, potentially easing the bottlenecks that keep families waiting for answers.
